DAX23.092 -0,8%Est505.515 -1,0%MSCI World4.343 -0,1%Top 10 Crypto11,72 -3,4%Nas22.273 +0,9%Bitcoin73.402 -0,7%Euro1,1515 ±0,0%Öl62,56 -1,0%Gold4.066 -0,3%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Rheinmetall 703000 Siemens Energy ENER6Y DroneShield A2DMAA RENK RENK73 Amazon 906866 Alphabet A (ex Google) A14Y6F Deutsche Telekom 555750 Tesla A1CX3T Lufthansa 823212 Palantir A2QA4J BASF BASF11 Infineon 623100 TKMS thyssenkrupp Marine Systems TKMS00 SAP 716460
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX geht bei über 23.000 Punkten ins Wochenende -- Wall Street höher -- Portfolio von NVIDIA -- Bitcoin & Co. tiefrot -- D-Wave, Novo Nordisk, Siemens Energy, DroneShield, Rheinmetall, RENK im Fokus
Top News
Die führenden Universitäten für ein erstklassiges Studium im Bereich Finanzen Die führenden Universitäten für ein erstklassiges Studium im Bereich Finanzen
Eli Lilly-Aktie fest: Novo Nordisk-Konkurrent erstmals über 1 Billion Dollar wert Eli Lilly-Aktie fest: Novo Nordisk-Konkurrent erstmals über 1 Billion Dollar wert
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Zenas BioPharma Aktie

Kaufen
Verkaufen
35,61 USD +0,70 USD +2,01 %
nachbörslich
BTT
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone

Marktkap.1,62 Mrd. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA40MUX

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS98937L1052

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolZBIO

Zenas BioPharma Aktien News

DatumMeistgelesen
PR NewswireSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Zenas BioPharma, Inc. (NASDAQ: ZBIO)
finanzen.netZenas BioPharma: Bilanzzahlen zum vergangenen Quartal
TraderFoxKurszieleTOP-5-Kursziele der Analysten am 28.10.25
Dow JonesMÄRKTE USA/Fest - Neue KI-Chips beflügeln Qualcomm
Dow JonesMÄRKTE USA/Rekordlauf geht weiter - Technologieaktien favorisiert
MotleyFoolChairman and CEO of Zenas BioPharma (ZBIO) Buys 36,928 Shares for $769,948
BenzingaZenas Biopharma Raises $120 Million To Secure Global Rights To Multiple Sclerosis Drug
finanzen.netZenas BioPharma legte die Bilanz zum abgelaufenen Quartal vor
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
PR NewswireZBIO Investors Have Final Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
PR NewswireInvestors who lost money on Zenas BioPharma, Inc.(ZBIO) should contact The Gross Law Firm about pending Class Action - ZBIO
PR NewswireZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO
PR NewswireDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
PR NewswireZenas BioPharma, Inc. Class Action: Levi & Korsinsky Reminds Zenas BioPharma, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 16, 2025 - ZBIO
PR NewswireZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
PR NewswireZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO
PR NewswireShareholders that lost money on Zenas BioPharma, Inc.(ZBIO) Urged to Join Class Action - Contact The Gross Law Firm to Learn More
PR NewswireINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
PR NewswireShareholders of Zenas BioPharma, Inc. Should Contact The Gross Law Firm Before June 16, 2025 to Discuss Your Rights - ZBIO
PR NewswireZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
PR NewswireZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO
PR NewswireZBIO STOCKHOLDERS: Contact Robbins LLP for Information About How to Lead the Class Action Against Zenas BioPharma, Inc.
PR NewswireZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
PR NewswireZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
PR NewswireZBIO Deadline: ZBIO Investors with Losses in Excess of $100K Have Opportunity to Lead Zenas BioPharma, Inc. Lawsuit Filed by The Rosen Law Firm
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
PR NewswireZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
finanzen.netZenas BioPharma: So viel setzte das Unternehmen zuletzt um
PR NewswireLevi & Korsinsky Reminds Zenas BioPharma, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 16, 2025 - ZBIO
PR NewswireZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Lawsuit Filed by The Rosen Law Firm
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
PR NewswireLevi & Korsinsky Notifies Shareholders of Zenas BioPharma, Inc.(ZBIO) of a Class Action Lawsuit and an Upcoming Deadline
PR NewswireZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
PR NewswireThe Gross Law Firm Notifies Shareholders of Zenas BioPharma, Inc.(ZBIO) of a Class Action Lawsuit and an Upcoming Deadline
PR NewswireZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
PR NewswireContact Levi & Korsinsky by June 16, 2025 Deadline to Join Class Action Against Zenas BioPharma, Inc.(ZBIO)
PR NewswireZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Zenas BioPharma News

Zenas BioPharma News: auf dieser Seite finden Sie alle Zenas BioPharma News und Nachrichten zur Zenas BioPharma Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Zenas BioPharma News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Zenas BioPharma News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.